Skip to content

Pfizer Stops 70% Omicron Hospitalizations in South Africa Study

  • Pfizer stops 70% of omicron hospitalizations, Discovery says
  • Prior infections in excess of 70% of population also cuts risk
Video player cover image
Pfizer Halts 70% Omicron Hospitalizations in S. Africa Study
Updated on

Follow our live coverage of this breaking news here.

Pfizer Inc. and BioNTech’s Covid-19 vaccine, as well as the shot developed by Johnson & Johnson, appear to largely prevent severe disease from the omicron variant, South African studies show.